Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO, UniPharma is considering both organic and inorganic development opportunities to further nurture its geographical expansion.

Being one of the best-established specialty distributors in Taiwan, UniPharma has been continuously broadening the scope of its operations since 2010. Where does the company stand now and what is its positioning among the Taiwanese and international healthcare industries?

"In the grand scheme of things, UniPharma’s core approach is to offer innovative answers to unmet medical needs arising from Taiwanese patients"